NR1H4 and metabolic disease: Interestingly, the oral administration of BSH inhibitors has demonstrated promise in the management of metabolic disorders, which achieves this by modulating intestinal FXR signaling through microbial function alteration and BA depolymerization reduction (Huang et al., 2019; Xie et al., 2020).